eHSCs Have the Potential to Transform Allogeneic Transplant and HSC Gene Therapies

Our eHSCs are designed to overcome key limitations of allogeneic donor and autologous gene-edited stem cell transplants. By inserting mRNA or DNA into stem cells, leading to expression of a modified receptor or protein, we can reprogram donor or gene-edited stem cells to have a transient proliferative and survival advantage over the patient’s existing cells to permit higher levels of engraftment without the need for toxic conditioning of the patient.

eHSCs have the potential to eliminate the need for donor T-cells, B-cells and NK-cells which are needed in unmodified donor HSC grafts to permit robust engraftment but can lead to graft versus host disease (“GVHD”), where the donor cells attack the patient’s tissues, resulting in the need for long-term immunosuppression therapies. eHSCs may expand the potential number of donors available for any given patient.

Key Issues Limit the Curative Potential Of Stem Cell Transplants


eHSCs Potential to Change to Allogeneic and Gene Therapy Transplant